STOCK TITAN

BCAX (NASDAQ: BCAX) insider details Rule 144 stock sales and plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

BCAX insider Ryan Cohlhepp filed a Rule 144 notice to sell 149 shares of the company’s common stock through UBS Financial Services on or around 01/15/2026, with an aggregate market value of $2,684.98. The filing reports that these shares were acquired on 05/12/2024 by exercising a stock option for cash. The notice indicates total common shares outstanding of 54,781,950, showing this planned sale is very small relative to the company’s share base.

Over the prior three months, Cohlhepp sold additional common shares in three equal blocks of 12,500 shares each on 10/15/2025, 11/21/2025, and 12/15/2025, with reported gross proceeds of $226,942.50, $225,587.50, and $233,547.50, respectively. The signer represents that he does not know of any undisclosed material adverse information about BCAX at the time of this notice.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What insider transaction is disclosed for BCAX in this Form 144?

The notice reports that Ryan Cohlhepp intends to sell 149 shares of BCAX common stock through UBS Financial Services on or about 01/15/2026, with an aggregate market value of $2,684.98.

How were the BCAX shares in the planned Rule 144 sale acquired?

The 149 BCAX common shares were acquired on 05/12/2024 via an exercise of a stock option, with payment made in cash on the same date.

How many BCAX shares are reported as outstanding in this filing?

The Form 144 lists 54,781,950 BCAX common shares as outstanding in connection with the reported sale.

What BCAX insider sales occurred in the past three months before this notice?

The filing shows that Ryan Cohlhepp sold 12,500 BCAX common shares on each of 10/15/2025, 11/21/2025, and 12/15/2025, for gross proceeds of $226,942.50, $225,587.50, and $233,547.50, respectively.

On which exchange are the BCAX shares in this Form 144 to be sold?

The planned sale of 149 BCAX common shares is listed for trading on the NASDAQ exchange.

What representation does the insider make about BCAX’s information in this notice?

By signing the notice, the seller represents that he does not know any material adverse information about BCAX’s current or prospective operations that has not been publicly disclosed.
Bicara Therapeutics

NASDAQ:BCAX

BCAX Rankings

BCAX Latest News

BCAX Latest SEC Filings

BCAX Stock Data

915.95M
45.05M
12.23%
93.98%
9.88%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON